Welcome to our dedicated page for BridgeBio Oncology Therapeutics SEC filings (Ticker: BBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported a Form 4 disclosing that Eli M. Wallace, who serves as Chief Executive Officer and a director, was granted a stock option on 10/02/2025. The option covers 1,614,400 shares of common stock with an exercise price of $12.44 per share and an expiration date of 10/01/2035. The option becomes exercisable in equal monthly installments equal to 1/48th of the total award, beginning on 10/02/2025, subject to continued service. The reporting person is shown as the direct holder of the option and the Form 4 was signed by an attorney-in-fact on 10/06/2025.